Pełna treść
2/2026
vol. 113
List do Redakcji
Relapse after Excision of Melanoma in situ
Institute of Oncology, Istanbul University, Turkey
Dermatol Rev/Przegl Dermatol 2026, 113, 107–108
Data publikacji online: 2026/07/31
Plik artykułu
- Patel V.R., Roberson M.L., Pignone M.P., Adamson A.S.: Risk of mortality after a diagnosis of melanoma in situ. JAMA Dermatol 2023, 159, 703-710.
- Naeser Y., Mikiver R., Ingvar C., Lambe M., Ullenhag G.J.: Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study. EClinicalMedicine 2023, 65, 102284.
- Mikkelsen J., Wagenblast A.L.H., Behrendt N., Lock-Andersen J.: Melanoma in situ with in-transit metastases. JPRAS Open 2017, 11, 37-42.
- Anderson J., Hamp A., Booms A., Carlson S.K.: Metastasis of a surgically excised melanoma in situ. J Dermatol Nurses Assoc 2022, 14, 170-172.
- Pantaleão L., Rochael M.C.: Study of 448 cases of melanoma in situ in two hospitals in Rio de Janeiro. An Bras Dermatol 2017, 92, 277-278.
- Bax M.J., Johnson T.M., Harms P.W., Schwartz J.L., Zhao L., Fullen D.R.: Detection of occult invasion in melanoma in situ. JAMA Dermatol 2016, 152, 1201-1208.
- Moyer J.S., Rudy S., Boonstra P.S., Kraft C., Chinn S.B., Baker S.R., et al.: Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. JAMA Dermatol 2017, 153, 282-288.
- Higgins H.W., Lee K.C., Galan A., Leffell D.J.: Melanoma in situ: part II. Histopathology, treatment, and clinical management. J Am Acad Dermatol 2015, 73, 193-203.
Copyright: © 2026 Polish Dermatological Association. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

